Laetitia Lemoine

List of Publications by Year
in descending order

21 papers	1,110 citations	858243 12 h-index	1255698 13 g-index
24 all docs	24 docs citations	24 times ranked	1953 citing authors

#	ARTICLE	IF	CITATIONS
1	Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimerâ€™s disease variants: AÎ²PParc and PSEN1DE9. Molecular Psychiatry, 2021, 26, 5609-5619.	4.1	16
2	Astroglial tracer BU99008 detects multiple binding sites in Alzheimerâ€™s disease brain. Molecular Psychiatry, 2021, 26, 5833-5847.	4.1	39
3	Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 84, 103-117.	1.2	4
4	Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimerâ€™s disease cases. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1093-1102.	3.3	22
5	Lack of fibrillar amyloid plaques but hypometabolism and astrogliosis in autosomal dominant variant AÃŸPParc Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 5471-5471.	4.1	0
6	Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue. Molecular Neurodegeneration, 2020, 15, 68.	4.4	18
7	Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1369-1382.	3.3	74
8	P4â€599: ANTEâ€MORTEM BINDING OF ¹⁸Fâ€THK5317 PET IN A CASE OF FTLD AND POSTâ€MORTEM COMPARISON OF TAU BINDING USING ³Hâ€THK5117 AND ³Hâ€MK6240. Alzheimer's and Dementia, 2019, 15, P1554.	0.4	0
9	Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1152-1163.	3.3	30
10	Tau PET imaging in neurodegenerative tauopathiesâ€”still a challenge. Molecular Psychiatry, 2019, 24, 1112-1134.	4.1	409
11	Tau positron emission tomography imaging in tauopathies: The added hurdle of offâ€target binding. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 232-236.	1.2	86
12	Tau PET imaging: present and future directions. Molecular Neurodegeneration, 2017, 12, 19.	4.4	220
13	Cortical laminar tau deposits and activated astrocytes in Alzheimerâ€™s disease visualised by 3H-THK5117 and 3H-deprenyl autoradiography. Scientific Reports, 2017, 7, 45496.	1.6	44
14	[P4â€“274]: COMPARISON OF BINDING PROPERTIES OF THK5117, THK5351, PBB3 AND T807 IN AUTOPSIES OF ALZHEIMER DISEASE CASES. Alzheimer's and Dementia, 2017, 13, P1390.	0.4	0
15	[ICâ€Pâ€189]: COMPARISON OF BINDING PROPERTIES OF THK5117, THK5351, PBB3 AND T807 IN AUTOPSIES OF ALZHEIMER DISEASE CASES. Alzheimer's and Dementia, 2017, 13, P139.	0.4	0
16	Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimer's Research and Therapy, 2017, 9, 96.	3.0	90
17	ICâ€Pâ€170: In Vitro Characterization of Fibrillar Amyloid, TAU Deposition, and Activated Astrocytes in Arctic AD Brain in Comparison With Sporadic AD Brain Using 3Hâ€PIB, 3Hâ€THK5117 and 3Hâ€Deprenyl. Alzheimer's and Dementia, 2016, 12, P124.	0.4	0
18	P1â€105: In vitro Characterization of Fibrillar Amyloid, TAU Deposition, and Activated Astrocytes in Arctic Alzheimer's Disease Brain in Comparison With Sporadic Alzheimer's Disease Brain Using 3Hâ€PIB, 3Hâ€THK5117 and 3Hâ€DEPRENYL. Alzheimer's and Dementia, 2016, 12, P442.	0.4	0

#	Article	IF	Citations
19	Visualization of regional tau deposits using 3H-THK5117 in Alzheimer brain tissue. Acta Neuropathologica Communications, 2015, 3, 40.	2.4	58
20	IC-P-212: CHARACTERIZATION OF THK5117 BINDING IN AD BRAIN TISSUE: IMPLICATION FOR DEVELOPMENT OF PET TAU IMAGING. , 2014, 10, P115-P115.		0
21	O1-12-04: CHARACTERIZATION OF THK5117 BINDING IN AD BRAIN TISSUE: IMPLICATION FOR DEVELOPMENT OF PET TAU IMAGING. , 2014, 10, P155-P155.		0